Vanguard Group
TNGX icon

Vanguard Group’s Tango Therapeutics TNGX Stock Holding History

Vanguard Group’s Portfolio TNGX Stock Details TNGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$59.8M Buy
6,750,977
+1,698,974
+34% +$14.6M ﹤0.01% 2073
2025
Q3 		$42.4M Buy
5,052,003
+1,025,203
+25% +$6.94M ﹤0.01% 2245
2025
Q2 		$20.6M Buy
4,026,800
+151,255
+4% +$374K ﹤0.01% 2541
2025
Q1 		$5.31M Sell
3,875,545
-109,680
-3% -$269K ﹤0.01% 3147
2024
Q4 		$12.3M Buy
3,985,225
+339,922
+9% +$1.58M ﹤0.01% 2837
2024
Q3 		$28.1M Buy
3,645,303
+350,731
+11% +$3.35M ﹤0.01% 2426
2024
Q2 		$28.3M Buy
3,294,572
+213,687
+7% +$1.65M ﹤0.01% 2394
2024
Q1 		$24.5M Buy
3,080,885
+101,673
+3% +$1.09M ﹤0.01% 2500
2023
Q4 		$29.5M Buy
2,979,212
+39,369
+1% +$342K ﹤0.01% 2421
2023
Q3 		$33.1M Buy
2,939,843
+197,624
+7% +$1.21M ﹤0.01% 2330
2023
Q2 		$9.1M Sell
2,742,219
-7,703
-0.3% -$27.7K ﹤0.01% 2998
2023
Q1 		$10.9M Buy
2,749,922
+35,110
+1% +$204K ﹤0.01% 2888
2022
Q4 		$19.7M Buy
2,714,812
+111,068
+4% +$781K ﹤0.01% 2635
2022
Q3 		$9.43M Sell
2,603,744
-408,174
-14% -$1.74M ﹤0.01% 2977
2022
Q2 		$13.6M Buy
3,011,918
+297,955
+11% +$1.8M ﹤0.01% 2828
2022
Q1 		$20.6M Buy
2,713,963
+1,267,198
+88% +$11M ﹤0.01% 2757
2021
Q4 		$15.8M Buy
1,446,765
+61,939
+4% +$745K ﹤0.01% 2962
2021
Q3 		$17.9M Buy
+1,384,826
New +$16.6M ﹤0.01% 2924

Other funds holding TNGX

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group's TNGX Position: Q4 2025 in Review

Vanguard Group increased its Tango Therapeutics (TNGX) stake by 34% in Q4 2025, buying an estimated $14.6M and bringing the position to 6,750,977 shares worth $59.8M. The position accounts for ﹤0.01% of the portfolio, ranked #2073.

Vanguard Group first reported a position in TNGX in Q3 2021 and has held it in 18 quarters since. 170 funds tracked by Wall St. Rank hold TNGX as of Q4 2025.

  • Vanguard Group held 6,750,977 shares of Tango Therapeutics worth $59.8M as of Q4 2025.
  • Vanguard Group bought 1,698,974 Tango Therapeutics shares in Q4 2025, an estimated $14.6M.
  • Tango Therapeutics made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #2073 holding.
  • Vanguard Group first reported a position in Tango Therapeutics in Q3 2021 and has held it in 18 quarters since.
  • 170 funds tracked by Wall St. Rank held Tango Therapeutics as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.